Latest Breaking News On - Yuko yoneyama - Page 1 : comparemela.com

AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease | Region

AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease | Region
eagletribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eagletribune.com Daily Mail and Mail on Sunday newspapers.

Japan
Tabeta
Mie
Massachusetts
United-states
Osaka
Switzerland
United-kingdom
Japanese
Sarah-sheikh
Gary-waanders
Chris-stamm

AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimers Disease

AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimers Disease
businesswireindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesswireindia.com Daily Mail and Mail on Sunday newspapers.

Tabeta
Mie
Japan
United-kingdom
United-states
Switzerland
Osaka
Japanese
Gary-waanders
Sarah-sheikh
Corey-davis
Andrea-pfeifer

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab TAK079 a Potential BestinClass AntiCD38 Monoclonal Antibody for Primary Immune Thrombocytopenia

TakedaTSE4502NYSETAK today announced positive topline results from a Phase 2 randomized doubleblind placebocontrolled study evaluating the safety tolerability and efficacy of mezagitamab TAK079 in patients with persistent or chronic primary immune thrombocytopenia ITP.

United-states
Osaka
Japan
Japanese
Chinwe-ukomadu
Yuko-yoneyama
Rodeghierof-international-journal-of-hematology
Takeda-pharmaceutical-company-limited
Exchange-commission
Development-in-fiscal-year
Drug-administration
Efficacy-results

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024
financialpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialpost.com Daily Mail and Mail on Sunday newspapers.

Canada
Osaka
Japan
United-states
Ottawa
Ontario
New-york
Japanese
Canadian
American
Joe-oconnor
Yuko-yoneyama

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK861 an Oral Orexin Agonist in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Takeda TSE4502NYSETAK today announced positive topline results from a randomized doubleblind placebocontrolled multiple dose Phase 2b trial evaluating TAK861 an oral orexin receptor 2 OX2R agonist in patients with narcolepsy type 1.

Japan
United-states
Osaka
Japanese
Yuko-yoneyama
Takeda-pharmaceutical-company-limited
Exchange-commission
Upcoming-scientific-congress
Key-secondary-endpoints-were-met
Narcolepsy-type
Generally-safe
Results-will